Earnings Release • Aug 15, 2013
Earnings Release
Open in ViewerOpens in native device viewer
News Details
Corporate | 15 August 2013 07:45
Eckert & Ziegler Back on Track
Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Half Year Results
15.08.2013 / 07:45
Press release
Eckert & Ziegler Back on Track
Berlin, August 15, 2013. Eckert & Ziegler AG, a specialist in isotope technology applications for medicine, science and industry (ISIN DE0005659700) performed much better in April through June than in the first quarter. Sales increased by 9 % and profit for the period more than doubled.
At EUR 55.3 million, sales for the first half of the year are, however, down 4 % year on year due to the weak start to the year. This was largely due to changes in organic sales. Sales dropped considerably in the Radiation Therapy segment due to expectedly sluggish sales of tumor irradiation equipment, the price drops in the prostate implant product category and the disposal of the unprofitable accessories business. Sales in the largest segment, Isotope Products, however, were only down minimally year on year. Overall, there are clear signs of a positive trend for the second half of the year as the company’s order books are full.
At EUR 6.9 million, EBIT in the first half of 2013 is down 31 % year on year. This is also due to the weak start to the year. In the Environmental Services segment, governmental price increases resulted in an adjustment in provisions for environmental restoration. The Radiopharma segment reported a rise in the share of low-margin sales (merchandise) and fewer development costs were capitalized. These were offset by extraordinary income in the Radiation Therapy segment (agreement with Core Oncology to repay a loan) and in the Isotope Products segment (court ruling on the reimbursement of disposal costs).
Profits after taxes and minority interests amounted to EUR 4.0 million, or EUR 0.75 per share, at the end of the first half of the year, down 27 % year on year. This decline is less than that seen with EBIT due to lower interest payments and a drop in the tax rate.
The Group expects sales to grow to around EUR 125 million for the financial year 2013 and net earnings after taxes and minority interests in the sum of EUR 2.15 per share.
To read the full report please click here: http://www.ezag.com/fileadmin/ezag/user-uploads/pdf/financial-reports/englisch/euz213e.pdf
With around 630 employees the Eckert & Ziegler Group is one of the world’s largest providers of isotope components for radiotherapy and nuclear medicine.
If you have any questions please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations, Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.com
End of Corporate News
15.08.2013 Dissemination of a Corporate News, transmitted by DGAP – a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
| Language: | English |
| Company: | Eckert & Ziegler Strahlen- und Medizintechnik AG |
| Robert-Rössle-Str.10 | |
| 13125 Berlin | |
| Germany | |
| Phone: | 49 30 941084-138 |
| Fax: | 49 30 941084-112 |
| E-mail: | [email protected] |
| Internet: | www.ezag.de |
| ISIN: | DE0005659700 |
| WKN: | 565970 |
| Listed: | Regulierter Markt in Frankfurt (Prime Standard), Stuttgart; Freiverkehr in Berlin, Düsseldorf, Hamburg, München |
| End of News | DGAP News-Service |
| - - - |
| 225958 15.08.2013 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.